From October 1, 2023 to December 18, 2023, the company has repurchased 73,300 shares, representing 0.62% for CAD 0.62 million. With this, the company has completed the repurchase of 380,000 shares, representing 3.17% for CAD 2.89 million under the buyback announced on December 13, 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.51 CAD | -1.62% | -1.39% | -7.70% |
Apr. 22 | BioSyent Inc.(TSXV:RX) dropped from S&P/TSX Venture Composite Index | CI |
Apr. 01 | BioSyent To Present At LD Micro New York Investor Conference | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.70% | 73.36M | |
+31.52% | 662B | |
+21.96% | 546B | |
-5.21% | 359B | |
+17.02% | 323B | |
+5.01% | 289B | |
+13.68% | 234B | |
+3.81% | 198B | |
-10.63% | 194B | |
+3.98% | 167B |
- Stock Market
- Equities
- RX Stock
- News BioSyent Inc.
- Tranche Update on BioSyent Inc. (TSXV: RX)'s Equity Buyback Plan announced on December 13, 2022.